Precision therapeutic strategies for advanced gastrointestinal stromal tumors. (PubMed, Cancer Metastasis Rev) - Sep 20, 2026 - "Imatinib, followed by later-line tyrosine kinase inhibitors, including sunitinib, regorafenib, ripretinib, and genotype-selected avapritinib, have substantially prolonged survival. In this review, we summarize the biological and molecular landscape of advanced GIST, as well as the current therapeutic strategies and major mechanisms of resistance. Finally, we highlight promising therapeutic strategies supported by preclinical and clinical evidence that may advance subtype-informed precision medicine."
Journal • Review • Gastrointestinal Cancer • Gastrointestinal Disorder • Gastrointestinal Stromal Tumor • Oncology • Sarcoma • KIT • PDGFRA
|
|
Akira Ooki; Hiroki Osumi; Keitaro Shimozaki; Kensei Yamaguchi; Shohei Udagawa
|